[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"stock-detail-ACIU":3,"homepage-market-summary":29,"stock-news-ACIU":170},{"ticker":4,"date":5,"profile":6,"quote":13},"ACIU","2026-10-01",{"name":7,"exchange":8,"sector":9,"industry":10,"description":11,"ceo":9,"employees":12,"headquarters":9,"founded":9},"AC Immune SA","Nasdaq",null,"Common Stock","AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.","122",{"close":14,"open":15,"high":16,"low":17,"prev_close":18,"change":19,"percent_change":20,"volume":21,"transactions":22,"vwap":23,"high_52w":24,"low_52w":25,"avg_volume_52w":26,"range_52w_percent":27,"record_count":28},2.81,2.64,2.835,2.57,2.62,0.19,7.25,352693.785098,3130,2.7364,19.97,1.43,316617.06004607974,7.4,2521,{"status":30,"indices":31,"watchlist":72,"sectors":95,"benchmarks":150},"success",[32,39,46,53,59,66],{"symbol":33,"name":34,"price":35,"change":36,"pct_change":19,"is_up":37,"sparkline":38,"date":5},"SPX","S&P 500",7666.45,14.91,true,"0.0,3.1 2.3,5.0 4.6,8.0 6.9,10.4 9.3,13.4 11.6,9.1 13.9,11.5 16.2,13.8 18.5,16.0 20.8,10.3 23.2,9.5 25.5,2.0 27.8,2.0 30.1,5.9 32.4,6.0 34.7,3.4 37.1,7.3 39.4,8.2 41.7,9.4 44.0,8.5",{"symbol":40,"name":41,"price":42,"change":43,"pct_change":44,"is_up":37,"sparkline":45,"date":5},"NDX","NASDAQ 100",30501.56,93.06,0.31,"0.0,11.8 2.3,11.3 4.6,11.6 6.9,12.2 9.3,14.7 11.6,12.6 13.9,14.5 16.2,16.0 18.5,15.9 20.8,12.0 23.2,10.5 25.5,4.0 27.8,2.0 30.1,4.0 32.4,4.0 34.7,3.0 37.1,5.6 39.4,5.1 41.7,4.5 44.0,3.8",{"symbol":47,"name":48,"price":49,"change":50,"pct_change":51,"is_up":37,"sparkline":52,"date":5},"DJI","DOW JONES",50927,21,0.04,"0.0,2.0 2.3,3.4 4.6,6.5 6.9,8.6 9.3,10.2 11.6,7.6 13.9,8.4 16.2,10.0 18.5,13.2 20.8,11.6 23.2,12.1 25.5,10.2 27.8,11.2 30.1,12.9 32.4,13.8 34.7,11.4 37.1,13.1 39.4,13.8 41.7,16.0 44.0,15.9",{"symbol":54,"name":55,"price":56,"change":57,"pct_change":51,"is_up":37,"sparkline":58,"date":5},"COMP","NASDAQ Composite",26871.6,10.53,"0.0,9.3 2.3,10.2 4.6,11.1 6.9,13.0 9.3,14.9 11.6,12.1 13.9,13.7 16.2,16.0 18.5,16.0 20.8,11.1 23.2,10.0 25.5,3.4 27.8,2.0 30.1,5.4 32.4,5.4 34.7,3.9 37.1,6.7 39.4,6.9 41.7,6.2 44.0,6.1",{"symbol":60,"name":61,"price":62,"change":63,"pct_change":64,"is_up":37,"sparkline":65,"date":5},"RUT","RUSSELL 2000",2790.2,11.3,0.41,"0.0,2.6 2.3,2.0 4.6,3.0 6.9,6.1 9.3,8.4 11.6,7.5 13.9,8.8 16.2,10.4 18.5,11.3 20.8,10.2 23.2,11.2 25.5,10.1 27.8,8.8 30.1,12.9 32.4,13.1 34.7,12.8 37.1,14.4 39.4,15.1 41.7,16.0 44.0,15.1",{"symbol":67,"name":68,"price":69,"change":70,"pct_change":44,"is_up":37,"sparkline":71,"date":5},"VIX","CBOE VIX",16.39,0.05,"0.0,15.6 2.3,14.8 4.6,10.2 6.9,7.3 9.3,2.0 11.6,9.7 13.9,4.9 16.2,4.5 18.5,2.5 20.8,11.3 23.2,13.7 25.5,13.5 27.8,16.0 30.1,12.3 32.4,10.4 34.7,13.5 37.1,8.8 39.4,8.9 41.7,7.8 44.0,7.6",[73,80,88],{"symbol":74,"name":75,"price":76,"change":77,"pct_change":78,"is_up":37,"sparkline":79,"date":5},"NVDA","NVIDIA Corp",230.86,2.48,1.09,"0.0,13.9 7.3,16.0 14.7,14.9 22.0,6.5 29.3,10.1 36.7,7.5 44.0,2.0",{"symbol":81,"name":82,"price":83,"change":84,"pct_change":85,"is_up":86,"sparkline":87,"date":5},"AAPL","Apple Inc",330.32,-2.7,-0.81,false,"0.0,6.9 7.3,8.2 14.7,2.0 22.0,5.2 29.3,16.0 36.7,11.7 44.0,14.9",{"symbol":89,"name":90,"price":91,"change":92,"pct_change":93,"is_up":86,"sparkline":94,"date":5},"TSLA","Tesla Inc",354.11,-0.7,-0.2,"0.0,2.0 7.3,3.1 14.7,6.1 22.0,13.6 29.3,16.0 36.7,15.0 44.0,15.3",[96,101,106,111,116,121,126,131,135,140,145],{"name":97,"etf":98,"change":99,"price":100,"is_up":37},"Technology","XLK",1.05,197.81,{"name":102,"etf":103,"change":104,"price":105,"is_up":37},"Financials","XLF",0.11,53.46,{"name":107,"etf":108,"change":109,"price":110,"is_up":86},"Healthcare","XLV",-1.32,166.2,{"name":112,"etf":113,"change":114,"price":115,"is_up":86},"Consumer Cycl","XLY",-0.03,108.81,{"name":117,"etf":118,"change":119,"price":120,"is_up":86},"Consumer Staples","XLP",-0.33,80.33,{"name":122,"etf":123,"change":124,"price":125,"is_up":37},"Energy","XLE",1.95,62.7,{"name":127,"etf":128,"change":129,"price":130,"is_up":37},"Industrials","XLI",0.99,168.64,{"name":132,"etf":133,"change":119,"price":134,"is_up":86},"Materials","XLB",48.54,{"name":136,"etf":137,"change":138,"price":139,"is_up":86},"Real Estate","XLRE",-0.56,40.68,{"name":141,"etf":142,"change":143,"price":144,"is_up":37},"Utilities","XLU",0.61,39.68,{"name":146,"etf":147,"change":148,"price":149,"is_up":86},"Comm Services","XLC",-0.93,109.94,[151,156,160,165],{"ticker":152,"name":153,"price":154,"change":155,"is_up":37},"SPY","SPDR S&P 500 ETF",763.99,0.18,{"ticker":157,"name":158,"price":159,"change":44,"is_up":37},"QQQ","Invesco QQQ Trust",742.03,{"ticker":161,"name":162,"price":163,"change":164,"is_up":37},"DIA","SPDR Dow Jones ETF",508.68,0.03,{"ticker":166,"name":167,"price":168,"change":169,"is_up":37},"IWM","iShares Russell 2000",279.06,0.42,{"ticker":4,"count":171,"articles":172},15,[173,179,185,191,197,203,209,214,219,224,230,235,240,243,248],{"title":174,"link":175,"pubDate":176,"description":177,"source":178},"After 100 weeks, AC Immune's Parkinson's trial met its main safety and immune-response goals. - Stock Titan","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiwAFBVV95cUxPUHp2NWdfSUw4MTVRNk41NG9abDU0RGhFdk5hNEdxRTQ5NTV6b3dZeUNlMFN4Vk94LUQ1MWxMbXVqX3llMmZfdEdZQ2d1MktZU0ZHdnhaSEZ5YWNTUmlfQm1wT2NxTU01WUlHX3ZXSDN0ODdOWVN4d1lucUF1Z01VT1lhTG95M25LUFJlb2lFaUNnVHlETnRTaFpITWUwQk5GVU5PLUdQR29XVXVWNE5yc1lRbFlGVHRBa0FrT3o3eEk?oc=5","Wed, 23 Sep 2026 11:00:00 GMT","After 100 weeks, AC Immune's Parkinson's trial met its main safety and immune-response goals. Stock Titan","Stock Titan",{"title":180,"link":181,"pubDate":182,"description":183,"source":184},"ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal - TradingView","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiwgFBVV95cUxOcHR6ZXFPaWtmTkZZbXdJYWphTGNVQ090VF9BVUY3Q19mcHNINmpRMGlhSDRweGtUTGJIenFMb2dxamJuYUdjQVZ3aVhCSHZOc2dheG04ZDBSVXJST3VEZVNRS1pmMWpUNGFERDd6S1pvN2tEM3p5ekZqZ043RjJsaUZCRkdkMTNRNHZqMGpLTkhROEJJc0ZuOU52YlhoU013T1JWOHJiX2lnSFhvbzU2VjRldng5R0NHNmFCcE9JUGgwdw?oc=5","Fri, 25 Sep 2026 15:02:00 GMT","ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal TradingView","TradingView",{"title":186,"link":187,"pubDate":188,"description":189,"source":190},"AC Immune posts trial data for Parkinson’s drug (ACIU:NASDAQ) - Seeking Alpha","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMihwFBVV95cUxNXzVNSUVqb09oWDJaM1ZaMjhhRUEteWdQTzFjR1dFd20walo3QUItZjlKejJURFVuVmhjMUViYklseGJVYnZnQ1ZpYWxoNXJoYjZ1R1JzUjBBeUUyUGtsQXhPTFNtVm1MNTd4N1lFYTR6WmFFMk1ybGFpazF3bjhzdmJUdklqWGM?oc=5","Wed, 23 Sep 2026 11:52:42 GMT","AC Immune posts trial data for Parkinson’s drug (ACIU:NASDAQ) Seeking Alpha","Seeking Alpha",{"title":192,"link":193,"pubDate":194,"description":195,"source":196},"IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026 - The Globe and Mail","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMi4gFBVV95cUxQbWNZcWItZjJtaHB4bkVZV0N0WEJIQkNUTDJQVmNPS2JJT0UzWFo0TDZGQVoySjlPMHU2WU5scFYyaDA0RjMyYmtsNkd2ZHRfT3NrSjQycW9lMFlNUkJYQml2XzdhaUdqTktLQ2o5ZndmM2NwLVBVazZGMkdJeXo5QTlKajV2blhsRWNOOGZQbTUtVWlhcEIwdTMzSlJEQ1pJVjI1ZGU1NTgwaGtpbTN0cEpNMUpoN09MT1p4X0JuRlpscTIzQzJydUd1NlVQazZGNmhPalZMME5YWGk1V1ZGcWt3?oc=5","Wed, 30 Sep 2026 15:36:00 GMT","IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026 The Globe and Mail","The Globe and Mail",{"title":198,"link":199,"pubDate":200,"description":201,"source":202},"Best Momentum Stock to Buy for September 30th - Yahoo Finance","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMinwFBVV95cUxQU3diSUhZbmk5ZEdURmRNMDdUQW9Wa2tJdU50b21yQ3JCZ3BJN010RVQ3UVBkRlJtMFJuYTJaQkR2VVl4NmI4MERpbEc4a21JamR6Z3pkbDloQlozWUYzZVpteXVOdnM0cFIzcnIwYmJtbGY2THNCV3ZCUFBaekxxOERERThLc3BRNzV5eFNuSmgzTTVrSEdrRmhGaVUwSzA?oc=5","Wed, 30 Sep 2026 10:43:00 GMT","Best Momentum Stock to Buy for September 30th Yahoo Finance","Yahoo Finance",{"title":204,"link":205,"pubDate":206,"description":207,"source":208},"H.C. Wainwright reiterates AC Immune stock rating on trial data - Investing.com","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMivgFBVV95cUxOTVMzaDgzcks5QTVGa3lYb2ZVZjJhN0tYTzdlMjRfR3E4TV9LWF9CRVEzYTQwUFVJRWJWa2hXSnBKVFdVSWd4NVdTd29lNmRKYi1MdVVIVG9UWk5RNmNwUTlwTzZjSHc0bklONU5yY3UyTktjLU92UmxNZlVSVGl5S1ctT09kZk94NUNmem5VODE3M1FvLWY0S0xqNEVkZ0wwZE5BR0VlQWJORVFRYVEyRkJFdEdvVkdnU0FFWV9R?oc=5","Thu, 24 Sep 2026 11:58:05 GMT","H.C. Wainwright reiterates AC Immune stock rating on trial data Investing.com","Investing.com",{"title":210,"link":211,"pubDate":212,"description":213,"source":178},"Shareholders elect Tom Graney to AC Immune (ACIU)'s board through the 2027 annual meeting. - Stock Titan","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMirAFBVV95cUxPdW5mQlN4V2VESEc3cmpFZmZXMUNDdWw0bWNBM1ZjUUk2RGNHMExUZmo2TTFleWV6T0dObUFvX0l1RHFrSndwMlljcTRNQ0piV3lwaU1VcUhUNVlHQzhIZmFaM2NVcDFxd2dzaDY5VEVZdnlkQ2w5MFNhQnRyQVFhOXFpUE1yaEdEaWZFS290bXI4Y0lfMzA4WVFEZVpNR1d5dEg5STlvWWxTdXpO?oc=5","Fri, 02 Oct 2026 12:02:45 GMT","Shareholders elect Tom Graney to AC Immune (ACIU)'s board through the 2027 annual meeting. Stock Titan",{"title":215,"link":216,"pubDate":217,"description":218,"source":190},"AC Immune: Buy Continued ACI-7104 Progress, PD, And Pipeline Expansions (NASDAQ:ACIU) - Seeking Alpha","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMirgFBVV95cUxOUFdDTGtnN05pd1R6Ml9MbkZyaHR5c1Bqal9uc3dfRzlvQk5odjZaRG1sTmh6bWZXQ2JvNTloRlJSZWNwdkYtLTFYQU05NEpLM0cwaEtuR2dvWkVfeVBoR1NZMHZZdk9abzhsbm9JaFpLd2RHZHBXdmN3MVJBU3FHbXV1Q2hCcWdSSE1iWk5HNGloT2RPbUFkYUxXRGUyT2ZuaW5BaTFrREwxRkJBbkE?oc=5","Thu, 24 Sep 2026 19:21:38 GMT","AC Immune: Buy Continued ACI-7104 Progress, PD, And Pipeline Expansions (NASDAQ:ACIU) Seeking Alpha",{"title":220,"link":221,"pubDate":222,"description":223,"source":184},"UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13% - TradingView","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMivwFBVV95cUxPeFRHTURhaEFmUDAweWpfNmVvNUloX0NlclpVYkR2S0NtUGpwMHlMZlozM1ZqV3EtNXBJUHZ2WEo0TmZwMkRYaEgtRkVSY01SZm4tbFFLaGtsZGVORWRBVy1HWWhpN0phT1R4aWNILUhSbTVsQ2d4Y1JrTVJJbUhuMHd6akx0aWRRd1NPZ2VoX2I5S19lQmJSclMxbUpNMGFnX3RkdzJ6QWc2bUszbHNvbkdEZ01KQk1WcWdZMVlmRQ?oc=5","Thu, 01 Oct 2026 15:16:00 GMT","UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13% TradingView",{"title":225,"link":226,"pubDate":227,"description":228,"source":229},"Zacks Investment Research - globes.co.il","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiYkFVX3lxTFAtZDBRdXJwMHh4RHpUVWJwbHA4dkdHTXMycmtvRXBWSjE5NGsxX3g0eXNtUVd1TFBkaHhjSjhlYzFfeko3LXM3SGpWZVpWc0dRcjRjcDYzR1RuMWtzLUZSa3JR?oc=5","Wed, 23 Sep 2026 07:00:00 GMT","Zacks Investment Research globes.co.il","globes.co.il",{"title":231,"link":232,"pubDate":233,"description":234,"source":184},"KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears - TradingView","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMivAFBVV95cUxOVU1scHBsVldJSFZQd2g3ZE5MODg4WjZocVhZbUFwMEZGX0t5bjg4UEdkcElfckM0YXB0MWdfWHk1MlNOelBfNUZwOVdsRWdlTnR6UG52Q256cktMejhoODBPVFZGakpQX29mNFRSSzk5ck5Vck5RNEo0YnJadjlraVZVVzhOcGpzbmVFOC1teHhjM1laeUZtdHFGR3JUM3BGeTRwTWRnVEZYUnYtSTdGd2djcGxEZWNlOVhnQw?oc=5","Tue, 29 Sep 2026 14:13:00 GMT","KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears TradingView",{"title":236,"link":237,"pubDate":238,"description":239,"source":196},"IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down - The Globe and Mail","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMi2wFBVV95cUxOMFcyeXNnREpnUjZhTFhGdTJRRi1oZjNUUFZ3dkNuaGtTMktZTFBrQ05lazhGbl9hSl9zc0stV0thSU9NX1ZvMkttUVZLNDlEU2k1QmVMODM0OTE3OFd1V2Q3clppakdhaEh5UUE5TFNhU3ZFSHBnall2ME5kTzZXeThhRk5MV052T1FFNERrNHdsdzZXdGtJbW1kOGY3VUNCQVZpbE82OTJFRXhBWUxfdnYtYXBaRE5XcGlPWWNFcWs2ajNFWmpqWUdaLV90QnFaN2RiYkJvNTJiM1k?oc=5","Thu, 24 Sep 2026 18:00:00 GMT","IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down The Globe and Mail",{"title":225,"link":241,"pubDate":242,"description":228,"source":229},"https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiYkFVX3lxTFBESWh2U2puN1hmXzdteG9qT1drOWFpeWtqb1M5MVY2d0Q2QkpRSkpVUlBMM3dzUDlxckNEVGZkUFFzcXBqTEQtZzkwQVNWOXlqLWlTa2JDNU5wRmhTOWM5QVh3?oc=5","Wed, 30 Sep 2026 20:53:02 GMT",{"title":244,"link":245,"pubDate":246,"description":247,"source":184},"FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce - TradingView","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMiuwFBVV95cUxQOU5Lc0hKR0FvZkYxdWk3anV1RENaV1V4bXVVSXNCWjkzY2F3Y2xrc1lJWGFYZ0dkWTB5UllVUGVGSUNSSUFLd1JkZkJJYllQWDlvdkRYV2FuSHpiVzM5QjR2b1FfeTFTQmVvUVFUMkpyVGZjVEhiVTNyclY1ck1mV3I2d0x4YkRuYUF5RzlYYnhnUFZ4T2Z6QzBGU19SbkZpNS1CYmotUHk4UUh2RDA4NXF3ODZuaVM2blk4?oc=5","Tue, 22 Sep 2026 16:23:00 GMT","FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce TradingView",{"title":249,"link":250,"pubDate":251,"description":252,"source":253},"AC Immune Adds Tom Graney to Board Following Extraordinary General Meeting - TipRanks","https:\u002F\u002Fnews.google.com\u002Frss\u002Farticles\u002FCBMixAFBVV95cUxNU1g5QkI1M1ZIYjliRDJkOGprTk5LRlBLWDdlZjV4czFZNU1HQkNYWVJrZzlXREhtZ0hWb2NhcE4tN3pkY0RGUzQ1bHpRMXZ6amQwaW9kRjlSamdmYjhhQXkwUWdGOEJNZVZqS2pnX0pDSWJXOFdrNmFCMF9tQks2TjVDQnJLSHhsQkVUOGlHWFFxNkMxV3d2cTBWa0ZPZHlyeGxHUTdXcUlZVzZqbk5BNW1kRzhVWmpvanM3cFYzaUgwQnFJ?oc=5","Fri, 02 Oct 2026 12:35:06 GMT","AC Immune Adds Tom Graney to Board Following Extraordinary General Meeting TipRanks","TipRanks"]